Published in Front Physiol on July 19, 2017
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Toll-like receptor signalling. Nat Rev Immunol (2004) 34.74
Toll-like receptors. Annu Rev Immunol (2001) 26.06
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 24.08
NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A (2006) 21.58
Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science (2003) 17.57
Toll-like receptors in innate immunity. Int Immunol (2005) 12.24
MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A (2007) 11.42
The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature (2009) 8.99
Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol (2007) 8.05
Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006) 6.00
Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol (2006) 6.00
Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J (1994) 5.70
Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A (2004) 5.58
Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science (2006) 5.30
Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol (2004) 5.12
Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol (2009) 5.05
Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med (2005) 4.92
MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity (2010) 4.65
Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev (2009) 4.55
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci U S A (2009) 3.97
TLRs and innate immunity. Blood (2008) 3.96
Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest (2005) 3.91
Pattern recognition receptors and control of adaptive immunity. Immunol Rev (2009) 3.91
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA (2013) 3.78
miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med (2011) 3.78
A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U S A (2006) 3.70
TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med (2008) 3.62
Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation (2002) 3.60
Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials (2010) 3.54
MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum (2009) 3.44
Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov (2010) 3.35
Toll-like receptors and Type I interferons. J Biol Chem (2007) 3.07
Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol (2009) 3.05
Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol (2007) 2.32
TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature (2010) 2.31
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med (2010) 2.31
Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev (2009) 2.30
TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol (2010) 2.09
Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol (2015) 2.08
Toll-like receptors. Curr Biol (2011) 2.06
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis (2010) 2.05
Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci U S A (2009) 2.04
The structural biology of Toll-like receptors. Structure (2011) 2.04
TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med (2008) 1.99
Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol (2004) 1.96
Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest (2004) 1.96
Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol (2005) 1.95
Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology (2005) 1.91
Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest (2002) 1.91
E5531, a pure endotoxin antagonist of high potency. Science (1995) 1.88
Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res (2010) 1.87
Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation (2006) 1.86
Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J Exp Med (2008) 1.84
Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol (2011) 1.83
A trio of microRNAs that control Toll-like receptor signalling. Int Immunol (2011) 1.79
The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature (2013) 1.78
Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther (2003) 1.75
Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis (2011) 1.75
Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med (1996) 1.70
Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc Natl Acad Sci U S A (2009) 1.70
Role of Toll-like receptors in gastrointestinal malignancies. Oncogene (2008) 1.69
Toll-like receptor 4 in CNS pathologies. J Neurochem (2010) 1.68
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release (2013) 1.64
TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol (2010) 1.63
Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv (2012) 1.62
Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron (2009) 1.60
Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol (2008) 1.59
Toll-like receptor signaling pathways. Front Immunol (2014) 1.58
Role of Toll-like receptors in the development of sepsis. Shock (2008) 1.57
TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol (2007) 1.48
Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol (2014) 1.48
TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol (2006) 1.44
Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res (2005) 1.44
The role of toll-like receptors in chronic inflammation. Int J Biochem Cell Biol (2009) 1.43
Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med (2010) 1.42
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol (2009) 1.39
Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation (2009) 1.38
Cutting edge: the nucleotide receptor P2X7 contains multiple protein- and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide. J Immunol (2001) 1.37
Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol (2011) 1.36
Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol (2007) 1.34
Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol (1999) 1.34
Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol (2008) 1.33
TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. J Exp Med (2008) 1.32
TGF-alpha regulates TLR expression and function on epidermal keratinocytes. J Immunol (2005) 1.31
Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice. Respir Res (2009) 1.29
Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation. J Immunol (2014) 1.24
Increased expression of toll-like receptor-2 and -4 on leukocytes from patients with sepsis. Shock (2004) 1.22
Toll-like receptor-4 mediates cigarette smoke-induced cytokine production by human macrophages. Respir Res (2006) 1.20
Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus. J Immunol (2009) 1.18
Role of toll-like receptor 4 in intimal foam cell accumulation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2010) 1.15
Comparison of expression of heat-shock protein 60, Toll-like receptors 2 and 4, and T-cell receptor gammadelta in plaque and guttate psoriasis. J Cutan Pathol (2007) 1.15
Ambient ultrafine particles provide a strong adjuvant effect in the secondary immune response: implication for traffic-related asthma flares. Am J Physiol Lung Cell Mol Physiol (2010) 1.13
Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus (1996) 1.13
MicroRNAs: new regulators of Toll-like receptor signalling pathways. Biomed Res Int (2014) 1.11
The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol (2011) 1.09
Inhibition of TLR2 promotes graft function in a murine model of renal transplant ischemia-reperfusion injury. FASEB J (2011) 1.08
Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension. Am J Physiol Heart Circ Physiol (2013) 1.08